Float and volume are looking good along with the percentage gain so far. Read the news and watch this into earnings! Just taking a little note here to check back later in my new scanner parameters!
I put an order our premarket to go short CRVS at the 3.50 level at 3.45. With a target half way back to the 3.00 level at 3.21. The reason I made my target half way to the 3.00 support is not entirely clear to me. Something about how the stock is not very extended, and how volume has been low. it felt a bit like it has been consolidating. And I didn't want to push...
I covered some CRVS today at a loss. I am currently too lazy to look and get all of the details.
Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and...
Hopefully you find the chart helpful in terms of Supports & Resistance etc. we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice. Thank you for taking time to consult our chart and we would really appreciate a like, follow or comment.
CRVS has a Bullish Bat HOP Levels: .24 cents .382 fib $3.75 .618 fib $4.93 on the weekly chart it is a strong green candle, but as for the Daily candle we do have a major gap, meaning we could refill that GAP between $2.53 - $3.57
Downward channel breakout insider a larger downward channel. Break 2.86 Target 3.43 and Target 2 5.43. Would consider stop of 2.37. Larger risk as stock as already just broken out. January $5.00 calls had 262 contracts traded on Friday. Price is 0.19 cents. $2.50 calls are 0.70.
Hello all, As you all may have noticed from doing your research that there has been a quantifiable spike in insider buying by the President and Director of Orbimed Advisors. On February 17th, 2021 there was an Initial Public Offering at $3.50/share. I have not made any extensive due diligence on the company yet, solely interested in the high amount of shares...
Multiple insider buying, huge institutional purchase at $3.50, and clear stop-loss below it. Low risk high reward play. First target is $5.
Pupm&Dump trading strategy idea. $CRVS is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,51; stop-loss — $6,3. Information about take-profits will be later. Do not view this idea as a...
Consolidation in TF wk is that's all I could say. Modulating immune system play role in cancer and infection. In cancer treatment targeted therapy and tailed play major role (High cost of drug of course) CRVS do the modulating immune system thing Now let's see what's CRVS do. What the physicians want is "When can we use this medication/protocol?" It's phase 3...
Leading diagonal completed, now in wave 2. Out of all stocks biotech is probably the most susceptible to wrong Elliott wave counts because they are volatile due to news and trial results having a heavy influence on the stock. Nevertheless, this is a view of what the future may hold.
In progress after breaking 15 mo downtrend. PT: $16.
Green lines are the stopping volume. It is in Accumulation phase now. Shall go higher